Teachers Retirement System of The State of Kentucky acquired a new stake in shares of ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 52,392 shares of the biotechnology company's stock, valued at approximately $1,047,000.
Several other large investors have also added to or reduced their stakes in the company. Hollencrest Capital Management bought a new stake in shares of ADMA Biologics during the 3rd quarter valued at $30,000. Larson Financial Group LLC bought a new stake in ADMA Biologics during the third quarter valued at about $31,000. National Bank of Canada FI purchased a new position in shares of ADMA Biologics in the third quarter valued at about $35,000. Quest Partners LLC bought a new position in shares of ADMA Biologics in the second quarter worth about $29,000. Finally, Harvest Fund Management Co. Ltd purchased a new stake in shares of ADMA Biologics during the third quarter worth about $62,000. Hedge funds and other institutional investors own 75.68% of the company's stock.
NASDAQ:ADMA opened at $17.70 on Thursday. The company has a market cap of $4.18 billion, a price-to-earnings ratio of 63.21 and a beta of 0.70. ADMA Biologics, Inc. has a 1 year low of $4.06 and a 1 year high of $23.64. The stock's 50 day simple moving average is $18.90 and its two-hundred day simple moving average is $16.24. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26.
ADMA Biologics (NASDAQ:ADMA - Get Free Report) last announced its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.15 EPS for the quarter, beating analysts' consensus estimates of $0.13 by $0.02. The firm had revenue of $119.84 million during the quarter, compared to the consensus estimate of $107.25 million. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. During the same quarter last year, the firm earned $0.01 EPS. As a group, equities analysts anticipate that ADMA Biologics, Inc. will post 0.52 earnings per share for the current fiscal year.
In other news, CFO Brad L. Tade sold 15,000 shares of the stock in a transaction that occurred on Friday, November 22nd. The stock was sold at an average price of $21.15, for a total value of $317,250.00. Following the sale, the chief financial officer now directly owns 199,433 shares in the company, valued at approximately $4,218,007.95. This represents a 7.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 3.70% of the company's stock.
A number of research analysts recently commented on the company. HC Wainwright boosted their price target on ADMA Biologics from $18.00 to $26.00 and gave the stock a "buy" rating in a report on Friday, November 8th. Raymond James boosted their target price on shares of ADMA Biologics from $18.00 to $25.00 and gave the stock a "strong-buy" rating in a report on Friday, November 8th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $20.00 target price on shares of ADMA Biologics in a research note on Friday, September 20th.
Check Out Our Latest Stock Report on ADMA Biologics
ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider ADMA Biologics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ADMA Biologics wasn't on the list.
While ADMA Biologics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.